We serve Chemical Name:Delphinidin 3-O-galactoside CAS:197250-28-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Delphinidin 3-O-galactoside
CAS.NO:197250-28-5
Synonyms:β-D-Galactopyranoside, 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3-yl;5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromeniumyl β-D-galactopyranoside
Molecular Formula:C21H21O12
Molecular Weight:465.384
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:465.102753
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like β-D-Galactopyranoside, 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3-yl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromeniumyl β-D-galactopyranoside physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromeniumyl β-D-galactopyranoside Use and application,β-D-Galactopyranoside, 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3-yl technical grade,usp/ep/jp grade.
Related News: Italy and Vietnam included Taiwan in banning flights from China, a move that they announced after the W.H.O. declared the coronavirus outbreak a global health emergency. Delphinidin 3-O-galactoside manufacturer The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January. Delphinidin 3-O-galactoside supplier But Vietnam then partly eased its ban, allowing flights from Hong Kong and Macau to continue, aviation authorities said. Delphinidin 3-O-galactoside vendor The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January. Delphinidin 3-O-galactoside factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.